PALO ALTO, Calif., March 16, 2020 /PRNewswire/ -- Varian (NYSE: VAR)
today announced its Halcyon™ 2.0 treatment system has
been approved by the China National Medical Products Administration
(NMPA), which allows the company to market this cancer treatment
system in China. This system
incorporates new imaging technologies, such as kV Cone-beam CT
(CBCT) and Iterative CBCT, to expand its capabilities and
ability to deliver high quality cancer care globally. This approval
further expands the global availability of Halcyon and access to
high-quality, cost-effective cancer treatments.
As an advanced cancer treatment system with a human-centered and
user-friendly design, Halcyon is engineered to revolutionize
clinical workflow, accelerate installation timeframes, expedite
commissioning, simplify training, and automate treatment. The
system is well suited to treat a majority of cancer patients,
offering advanced treatments for lung, prostate, breast, head &
neck, and many other forms of cancer.
Halcyon 2.0 features kV CBCT and Iterative CBCT imaging for
better soft tissue definition. The system is capable of kV CBCT
images in approximately 15 seconds. This enhanced imaging
capability helps ensure proper patient positioning while also
accelerating the treatment workflow.
Halcyon is supported by Varian's Eclipse™ treatment planning
system. This software creates an optimized radiotherapy treatment
plan based on a physician's dose instructions and information about
the size, shape, and location of the tumor to be treated with
radiation. The Eclipse software incorporates unique features such
as RapidPlan™ knowledge-based planning, multi-criteria
optimization (MCO), and Graphics Processing Unit (GPUs) support,
which are all designed to enable clinics to efficiently create the
highest quality plans.
"We are very excited to receive this approval and make
Halcyon 2.0 available to clinicians in China," said Chris
Toth, president Varian Oncology Systems. "The original
Halcyon system has already been well received in the country and
has allowed clinicians to treat thousands of patients. These new
imaging capabilities will play an important role in further
accelerating the patient workflow and proving the opportunity to
treat more patients."
For more information on Halcyon, visit
www.varian.com/halcyon.
About Varian
At Varian, we envision a world without
fear of cancer. For more than 70 years, we have developed, built
and delivered innovative cancer care technologies and solutions for
our clinical partners around the globe to help them treat millions
of patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 10,000 employees across 70 locations
keep the patient and our clinical partners at the center of our
thinking as we power new victories in cancer care. Because, for
cancer patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow
@VarianMedSys on Twitter.
Press Contact
Mark Plungy
Director, Global Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
Anshul Maheshwari
Vice President, Investor Relations
+1 (650) 424-5631
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-halcyon-2-0-treatment-system-receives-china-nmpa-approval-301023336.html
SOURCE Varian